Arch Resources (ARCH) Competitors

Cerevel Therapeutics (NASDAQ:CERE) and Arch Resources (NYSE:ARCH) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, community ranking, earnings, valuation and profitability.

Does the media prefer CERE or ARCH?

In the previous week, Arch Resources had 15 more articles in the media than Cerevel Therapeutics. MarketBeat recorded 28 mentions for Arch Resources and 13 mentions for Cerevel Therapeutics. Arch Resources' average media sentiment score of 0.76 beat Cerevel Therapeutics' score of 0.28 indicating that Cerevel Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cerevel Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Arch Resources	8 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do institutionals & insiders have more ownership in CERE or ARCH?

87.7% of Cerevel Therapeutics shares are held by institutional investors. Comparatively, 88.1% of Arch Resources shares are held by institutional investors. 5.1% of Cerevel Therapeutics shares are held by company insiders. Comparatively, 5.4% of Arch Resources shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Which has higher valuation and earnings, CERE or ARCH?

Arch Resources has higher revenue and earnings than Cerevel Therapeutics. Cerevel Therapeutics is trading at a lower price-to-earnings ratio than Arch Resources, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cerevel Therapeutics	N/A	N/A	-$432.84M	-$2.73	-16.34
Arch Resources	$3.15B	0.82	$464.04M	$17.00	8.39

Which has more volatility and risk, CERE or ARCH?

Cerevel Therapeutics has a beta of 1.4, indicating that its share price is 40% more volatile than the S&P 500. Comparatively, Arch Resources has a beta of 0.63, indicating that its share price is 37% less volatile than the S&P 500.

Does the MarketBeat Community prefer CERE or ARCH?

Arch Resources received 374 more outperform votes than Cerevel Therapeutics when rated by MarketBeat users. However, 66.52% of users gave Cerevel Therapeutics an outperform vote while only 61.73% of users gave Arch Resources an outperform vote.

Company	Underperform	Outperform
Cerevel Therapeutics	Outperform Votes 155 66.52%	Underperform Votes 78 33.48%
Arch Resources	Outperform Votes 529 61.73%	Underperform Votes 328 38.27%

Do analysts rate CERE or ARCH?

Cerevel Therapeutics presently has a consensus price target of $42.67, suggesting a potential downside of 4.38%. Arch Resources has a consensus price target of $177.00, suggesting a potential upside of 24.13%. Given Cerevel Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Arch Resources is more favorable than Cerevel Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cerevel Therapeutics	0 Sell rating(s)	8 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.11
Arch Resources	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50

Is CERE or ARCH more profitable?

Arch Resources has a net margin of 10.89% compared to Arch Resources' net margin of 0.00%. Cerevel Therapeutics' return on equity of 22.32% beat Arch Resources' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cerevel Therapeutics	N/A	-98.94%	-45.07%
Arch Resources	10.89%	22.32%	13.31%

Summary

Arch Resources beats Cerevel Therapeutics on 14 of the 17 factors compared between the two stocks.